Vivus Prescriptions

Quote
Anonymous said:
I have never heard so many cry babies in my life. Management is out and new leadership is in and you guys still complain. You got what you wished for and the complaining continues. So what is the deal now!!!! New management has no idea what they are doing just like the previous management? I suggest you take the effort that you use to complain and refocus that energy into your work.
Click to expand...

DMs Einstein
 












What are the SE idiot? You have no clue about this drug or why the numbers started off slow. Has nothing to do with the lack of retail initially. Since retail sales flat??? Once again you are an idiot. Yes, Einstein they were flat for 2 weeks but overall since retail has launched they are up over 50%. So go read another Arena article and jump to some more ignorant conclusions.




Anonymous said:
Aren't we a little sensitive.
What side effects?? Read here:

https://www.qsymia.com/#isi-content

There are 1 of 2 reasons why Qsymia sales are so anemic. 1) The sales force is completely useless. Since retail has opened up sales has been flat or modestly up single digits. 2) Doctors are just hesitant to prescribe it because of the side effects. Let's not rule out it could be both. Listen, little bitch, numbers don't lie.
Click to expand...
 






Anonymous said:
What are the SE idiot? You have no clue about this drug or why the numbers started off slow. Has nothing to do with the lack of retail initially. Since retail sales flat??? Once again you are an idiot. Yes, Einstein they were flat for 2 weeks but overall since retail has launched they are up over 50%. So go read another Arena article and jump to some more ignorant conclusions.
Click to expand...

It's easy to be up 50% when you start from ZERO.
 






3X that of Belviq and growing faster - despite a larger base and longer on market. Should be the other way around!! Belviq - without REMS and retail pharmacy from the start should be taking off - but it is NOT.
 




































Anonymous said:
Looks like you are missing your sales quota again. Rough day in the market. Hope tomorrow weekly script sales are not an indication of today's stock price.
Click to expand...

Lets see ...today's weekly IMS data (yahoo finance) indicated Qsymia up 10% and Belviq 0% - FLAT. I am not shareholder - but you can not compare these products clinically. Belviq sucks.
 


















Happens in my district too. You are so fortunate to have left. Highly unethical for both parties. Not everyone treated the same. Makes one wonder if it is encouraged by regional management to be unethical.
 






PTYou I'm still waiting for the little idiot who didn't know what he was talking about when referring to "ALL" the SE's with Qsymia. Let's see what is in the news today.......

As for Arena’s obesity treatment, Belviq, Cowen says it is staying “on the sidelines.”
“Belviq has a role in the new obesity landscape, but its efficacy is modest, and its safety profile is not without its issues,” the brokerage says.

“Our survey points to Qsymia as the obesity agent with the strongest efficacy. We also view its retail pharmacy availability and recent board changes as strong positives for Vivus,” the Cowen note said. The brokerage says it surveyed 50 obesity specialists and 50 primary care physicians and found each group identified Qsymia as the most effective treatment.

QSYMIA- MOST EFFECTIVE and STRONGEST EFFICACY
Belviq- Efficacy MODEST, SAFETY ISSUES and STAY YOUR ASS ON THE SIDELINES

GAME OVER.............THANKS FOR PLAYING!!!!!!!!!!!!!!!
 
Last edited by a moderator:






Top Bottom
Back
Quote